Mire-Sluis A R
Division of Immunobiology, National Institute for Biological Standards and Control, Potters Bar, Herts, UK.
Dev Biol Stand. 1999;97:3-9.
Cytokines (including growth factors) are playing an ever-increasing role in the therapy of human disease. The rapidity by which new cytokines are discovered, cloned and enter the clinics has placed a burden on control authorities and manufacturers to ensure their safety, quality and efficacy. The appropriate characterisation of these proteins plays a vital role in ensuring the development of cytokines as useful therapeutic agents. Highly sophisticated physicochemical techniques exist that can produce specific information about the structure and composition of cytokines including methods such as nuclear magnetic resonance (NMR) and mass spectrometry. However, even a bank of such techniques cannot yet predict the biological activity of cytokines. Biological assays are essential to assess the potency of cytokines and can take several forms, from in vivo assays to in vitro cell-line bioassays and more recently biochemically-based assays. Bioassays require a biological reference standard to define an appropriate unit that can be used to assess the potency of a biological therapeutic. However, bioassay-derived potency is a quality issue and should not have an impact on the perceived efficacy of a biological therapeutic.
细胞因子(包括生长因子)在人类疾病治疗中发挥着越来越重要的作用。新细胞因子被发现、克隆并进入临床的速度给监管当局和生产商带来了确保其安全性、质量和有效性的负担。对这些蛋白质进行恰当的表征对于确保细胞因子成为有用的治疗药物起着至关重要的作用。现有的高度复杂的物理化学技术能够产生有关细胞因子结构和组成的特定信息,包括核磁共振(NMR)和质谱等方法。然而,即便有一系列这样的技术,目前仍无法预测细胞因子的生物活性。生物学测定对于评估细胞因子的效力至关重要,其形式多样,从体内测定到体外细胞系生物测定,以及最近基于生物化学的测定。生物学测定需要一个生物学参考标准来定义一个合适的单位,用于评估生物治疗药物的效力。然而,源自生物学测定的效力是一个质量问题,不应影响对生物治疗药物疗效的认知。